Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas

[1]  R. Benjamin,et al.  High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Grochow,et al.  Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  W. Elliott,et al.  Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. , 1990, Cancer research.

[4]  C. Temple,et al.  New anticancer agents: chiral isomers of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-7-car bamate . , 1989, Journal of medicinal chemistry.

[5]  W. Waud,et al.  Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. , 1987, Cancer research.

[6]  D. J. Adamson,et al.  Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines. , 1983, Cancer research.

[7]  D. J. Adamson,et al.  Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928). , 1982, Cancer research.

[8]  B. Hoogstraten,et al.  Dose response evaluation of adriamycin in human neoplasia , 1977, Cancer.

[9]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[10]  I. Barasoain,et al.  Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. , 1994, Cancer research.